Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Question for Whalewatcher

<< Previous

Bullboard Posts

Next >>

Comment by C10H12N2on Dec 29, 2021 7:23pm

78 Views

Post# 34269377

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Question for Whalewatcher

What I think is you are a clown and should direct your posts to someone else.
What I think beyond your clownship is irrelevant in these back and forth threads with you.
Hence, I am blocking your posts ASAP because I find none of them helpful to anyone and especially to me.
I lose brain cells ranting back and forth with you.
Henceforth, speak to the wind child.

<< Previous

Bullboard Posts

Next >>

The Market Online’s Weekly Gold Report – Nov. 13, 2024